{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:44:26Z","timestamp":1791510266264,"version":"4.3.4"},"reference-count":17,"publisher":"Portland Press Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":192,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tuberous sclerosis complex (TSC) 1 and 2 function as tumor suppressors by inactivating the mammalian target of rapamycin (mTOR) pathway. Although the effect of platinum on TSC function has been studied, associations between TSC gene variants and survival of cancer patients treated with platinum-based chemotherapy were not evaluated. Genetic variants of TSC1 and TSC2 were identified by next-generation sequencing and selected for further clinical evaluation based on predetermined criteria. Associations of the gene variants with treatment outcomes (progression-free survival, PFS; overall survival, OS) were evaluated in testing and validation sets of patients with advanced non-small-cell lung cancer (NSCLC). Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with the multivariable Cox model. The TSC1 Met322Thr (rs1073123) variant met the criteria for further analysis in testing and validation sets each containing 183 patients. The median PFS for the 366 patients was 4.9 months. Fifty-three patients (14.5%) had the TSC1 (Met322Thr or Thr322Thr) variant. TSC1 Met322Thr associated with longer PFS in the testing set (HR adjusted for age, gender, smoking habits, Eastern Cooperative Oncology Group performance status, histology, and stage [aHR] and 95% CI: 0.63 and 0.45\u20130.87, Cox P=0.009), and this was confirmed in the validation set (aHR and 95% CI: 0.58 and 0.36\u20130.93, Cox P=0.004). However, no association was found between the TSC1 gene variant and OS. These findings suggest that the TSC1 gene variant is an important predictive marker for platinum doublet chemotherapy outcomes in NSCLC patients.<\/jats:p>","DOI":"10.1042\/bsr20181426","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T17:21:36Z","timestamp":1551892896000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet"],"prefix":"10.1042","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-8369","authenticated-orcid":false,"given":"Jeong-Seon","family":"Ryu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Inha University Hospital, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun\u00a0Hyeok","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inha University Hospital, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inha University Hospital, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min\u00a0Jeong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inha University Hospital, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi\u00a0Hwa","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inha University Hospital, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung\u00a0Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inha University Hospital, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"2021111619324414300_B1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2021111619324414300_B2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbrc.2010.03.029","article-title":"Role of the Akt\/mTOR survival pathway in cisplatin resistance in ovarian cancer cells","volume":"394","author":"Peng","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111619324414300_B3","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1158\/0008-5472.CAN-06-4261","article-title":"AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin\/p70S6K1 pathway","volume":"67","author":"Liu","year":"2007","journal-title":"Cancer Res."},{"key":"2021111619324414300_B4","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.1158\/1078-0432.CCR-10-0020","article-title":"cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor\/phosphatidylinositol 3-kinase\/AKT pathway confers resistance to cisplatin in human papillomavirus 16\/18-infected lung cancer","volume":"16","author":"Wu","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"2021111619324414300_B5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2010.04.008","article-title":"PI3K\/PTEN\/AKT\/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy","volume":"71","author":"Pu","year":"2011","journal-title":"Lung Cancer"},{"key":"2021111619324414300_B6","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1038\/emm.2016.16","article-title":"AMPK activators: mechanisms of action and physiological activities","volume":"48","author":"Kim","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"2021111619324414300_B7","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1074\/jbc.M704432200","article-title":"Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53","volume":"283","author":"Kim","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2021111619324414300_B8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"2021111619324414300_B9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021111619324414300_B10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1200\/JCO.2013.50.5453","article-title":"Prognostic impact of minimal pleural effusion in non-small-cell lung cancer","volume":"32","author":"Ryu","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"2021111619324414300_B11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"2021111619324414300_B12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"2021111619324414300_B13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","article-title":"The randomization and stratification of patients to clinical trials","volume":"27","author":"Zelen","year":"1974","journal-title":"J. Chronic. Dis."},{"key":"2021111619324414300_B14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly"},{"key":"2021111619324414300_B15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ccr.2006.08.007","article-title":"Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival","volume":"10","author":"Ghosh","year":"2006","journal-title":"Cancer Cell"},{"key":"2021111619324414300_B16","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2021111619324414300_B17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jnci\/djk091","article-title":"When you look matters: the effect of assessment schedule on progression-free survival","volume":"99","author":"Panageas","year":"2007","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181426\/842069\/bsr-2018-1426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20181426\/842069\/bsr-2018-1426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:23:10Z","timestamp":1637094190000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/3\/BSR20181426\/111058\/Survival-prediction-of-tuberous-sclerosis-complex"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,29]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20181426","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3]]},"article-number":"BSR20181426"}}